tenofovir + abacavir + efavirenz — Competitive Intelligence Brief

tenofovir + abacavir + efavirenz (tenofovir + abacavir + efavirenz) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NRTI + NNRTI). Area: Infectious Disease / Virology.

marketed Antiretroviral combination therapy (NRTI + NNRTI) HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

tenofovir + abacavir + efavirenz (tenofovir + abacavir + efavirenz) — Hospital Clinic of Barcelona. This combination of three antiretroviral drugs inhibits HIV replication by blocking reverse transcriptase and integrase enzymes, preventing the virus from copying its genetic material and integrating into host cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
tenofovir + abacavir + efavirenz TARGET	tenofovir + abacavir + efavirenz	Hospital Clinic of Barcelona	marketed	Antiretroviral combination therapy (NRTI + NNRTI)	HIV reverse transcriptase
Lamivudine / Abacavir Sulfate	Lamivudine / Abacavir Sulfate	GlaxoSmithKline	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
Combivir+Reyataz	Combivir+Reyataz	Hospital Clinic of Barcelona	marketed	Antiretroviral combination therapy (NRTI + protease inhibitor)	HIV reverse transcriptase; HIV protease
Switch to B/F/TAF	Switch to B/F/TAF	University of Nairobi	marketed	Antiretroviral combination (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
DTG/3TC/ABC + ELV/COBI/FTC/TAF	DTG/3TC/ABC + ELV/COBI/FTC/TAF	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Dolutegravir/Lamivudine	Dolutegravir/Lamivudine	Saint Michael's Medical Center	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase; HIV reverse transcriptase
Sofosbuvir, Ribavirin, and Stribild	Sofosbuvir, Ribavirin, and Stribild	Saint Michael's Medical Center	marketed	Direct-acting antiviral (DAA) combination; antiretroviral combination	HCV NS5B RNA polymerase; HIV integrase; HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NRTI + NNRTI) class)

1. GlaxoSmithKline · 2 drugs in this class
2. Clinical Trial Agency of HIV Study Group · 1 drug in this class
3. Hospital Clinic of Barcelona · 1 drug in this class
4. Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · 1 drug in this class
5. National Center for AIDS/STD Control and Prevention, China CDC · 1 drug in this class
6. Peking Union Medical College Hospital · 1 drug in this class
7. Sheba Medical Center · 1 drug in this class
8. Azienda Ospedaliera San Gerardo di Monza · 1 drug in this class
9. University of KwaZulu · 1 drug in this class